小川 浩司

小川 浩司

助教

学歴

1990年3月
北海道立札幌北高等学校卒業
1997年3月
大阪市立大学医学部卒業
2006年3月
北海道大学大学院医学研究科病態制御学専攻医学博士課程修了

職務経歴

1997年5月
大阪市立大学医学部付属病院 研修医
1998年4月
北海道大学医学部付属病院 研修医
1999年4月
札幌厚生病院消化器内科、循環器内科 医師
2000年4月
市立稚内病院内科 医師
2002年4月
市立札幌病院消化器科 医師
2003年4月
北海道大学第3内科 医師
2006年4月
市立函館病院消化器内科 医長
2014年4月
北海道大学病院消化器内科 助教

専門分野

  • 消化器肝臓病学

所属学会・資格

  • 日本内科学会 認定内科医 総合内科専門医
  • 日本肝臓学会 専門医 指導医 東部会評議員
  • 日本消化器病学会 専門医 指導医 北海道支部評議員
  • 日本消化器内視鏡学会 専門医
  • 日本超音波医学会

論文(英文のみ)

  1. Natsuizaka M, Hige S, Ono Y, Ogawa K, Nakanishi M, Chuma M, Yoshida S, Asaka M : Long-terrm follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    J Viral Hepat. 2005 Mar;12(2):154-9.
  2. Chuma M, Hige S, Nakanishi M, Ogawa K, Natsuizaka M, Yamamoto Y, Asaka M.
    8-Hydroxy-2-deoxy-quanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
    J Gastroenterol Hepatol. 2008 Sep; 23(9): 1431-6.
  3. Ogawa K, Hige S, Nakanishi M, Yamamoto Y, Chuma M, Nagasaka A, Asaka M : Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C.
    Antivir Ther. 2009; 14(4): 513-22.
  4. Chuma M, Taguchi H, Yamamoto Y, Shimizu S, Nakanishi M, Ogawa K, Sho T, Horimoto H, Kobayashi T, Nakai M, Terashita K, Sakuhara Y, Abo D, Tsukuda Y, Tsunematsu S, Hige S, Kato M, Shirato H, Asaka M.
    Efficacy of therapy for advanced hepatocellular carcinoma ; intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation.
    J Gastroenterol Hepatol. 2011 Jul;26(7): 1123-32.
  5. Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, Nakanishi M, Ogawa K, Chuma M, Sakamoto N, Asaka M.
    Anemia and thronbocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.
    J Gastroenterol. 2012 Nov;47(11): 1228-37.
  6. Yamato H, Kawakami H, Takagi K, Ogawa K, Hatanaka K, Yamamoto Y, Naruse H, Kawakubo K, Sakamoto N.
    Acute pancreatitis caused by Anisakis.
    Gastrointest Endosc. 2014 Apr;79(4):676.
  7. Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kudo M, Chuganji Y, Tsukuda Y, Tsunematsu S, Sato F, Terashita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Fujita Y, Abe R, Taniguchi M, Nakagawa M, Asahina Y, Sakamoto N.
    Serum granulysin levels as a predictor of serious telaprever-induced dermatological reactions.
    Hepatol Res. 2015 Aug,40(6):837-45.
  8. Tsunematsu S, Chuma M, Kamiyama T, Miyamoto N, Yabusaki S, Hatanaka K, Mitsuhashi T, Kamachi H, Yokoo H, Kakisaka T, Tsuruga Y, Orimo T, Wakayama K, Ito J, Sato F, Terashita K, Nakai M, Tsukuda Y, Sho T, Suda G, Morikawa K, Natsuizaka M, Nakanishi M, Ogawa K, Taketomi A, Matsuno Y, Sakamoto N.
    Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma.
    Abdom Imaging. 2015 Aug; 40(6): 1492-9.
  9. Maehara O, Sato F, Natsuizaka M, Asano A, Kubota Y, Itoh J, Tsunematsu S, Terashita K, Tsukuda Y, Nakai M, Sho T, Suda G, Morikawa K, Ogawa K, Chuma M, Nakagawa K, Ohnishi S, Komatsu Y, Whelan KA, Nakagawa H, Takeda H, Sakamoto N.
    A pivotal role of Kruppel-like factor 5 in regulation of cancer stem-like cells in hepatocellular carcinoma.
    Cancer Biol Ther. 2015 Oct; 16(10): 1453-61.
  10. Ito J, Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kumagai K, Kikuchi H, Miyagishima T, Kobayashi T, Kimura M, Yamasaki K, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Terashita K, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
    Hepatol Res. 2016 Feb 20. doi: 10.1111/hepr.12685. [Epub ahead of print]
  11. Terashita K, Chuma M, Hatanaka Y, Hatanaka K, Mitsuhashi T, Yokoo H, Ohmura T, Ishizu H, Muraoka S, Nagasaka A, Tsuji T, Yamamoto Y, Kurauchi N, Shimoyama N, Toyoda H, Kumada T, Kaneoka Y, Maeda A, Ogawa K, Natsuizaka M, Kamachi H, Kakisaka T, Kamiyama T, Taketomi A, Matsuno Y, Sakamoto N.
    ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma.
    J Clin Pathol. 2016 Jul;69(7):593-9.
  12. Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Yamasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terashita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N.
    Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
    J Gastroenterol. 2016 Jul;51(7):733-40.
  13. Tsunematsu S, Suda G, Yamasaki K, Kimura M, Takaaki I, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Kamiyama T, Taketomi A, Sakamoto N.
    Combination of neutrophil-to-lymphocyte ratio and early des-γ-carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma.
    Hepatol Res. 2016 Jul 16. doi: 10.1111/hepr.12775. [Epub ahead of print]
  14. Tsunematsu S, Suda G, Yamasaki K, Kimura M, Izumi T, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Tanaka Y, Watashi K, Wakita T, Sakamoto N.
    Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.
    J Med Virol. 2017 Feb;89(2):267-275.
  15. Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.
    Hepatol Res. 2016 Dec 12. doi: 10.1111/hepr.12851. [Epub ahead of print]
  16. Suda G, Ogawa K, Kimura M, Nakai M, Sho T, Morikawa K, Sakamoto N.
    Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.
    J Clin Transl Hepatol. 2016 Dec 28;4(4):320-327.
  17. Kondo S, Takagi K, Nishida M, Iwai T, Kudo Y, Ogawa K, Kamiyama T, Shibuya H, Kahata K, Shimizu C.
    Computer-Aided Diagnosis of Focal Liver Lesions Using Contrast-Enhanced Ultrasonography with Perflubutane Microbubbles.
    IEEE Trans Med Imaging. 2017 Jan 26. doi: 10.1109/TMI.2017.2659734. [Epub ahead of print]
  18. Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M, Umemura M, Ito J, Izumi T, Nakai M, Sho T, Natsuizaka M, Morikawa K, Tsubota A, Shimada N, Iio E, Tanaka Y, Sakamoto N; NORTE Study Group.
    Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    J Gastroenterol. 2017 Mar 18. doi: 10.1007/s00535-017-1328-z. [Epub ahead of print]
  19. Tsukuda Y, Suda G, Tsunematsu S, Ito J, Sato F, Terashita K, Nakai M, Sho T, Maehara O, Shimazaki T, Kimura M, Morikawa K, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Sakamoto N.
    Anti-adipogenic and antiviral effects of l-carnitine on hepatitis C virus infection.
    J Med Virol. 2017 May;89(5):857-866.